StockData
BlossomHill Therapeutics, Inc. logo

BlossomHill Therapeutics, Inc. (BLSM) stock

BLSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$15.13+1.48 (+10.84%)

Close on Nov 17, 2026Market cap $38.56MP/E –Yield –

BlossomHill Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$21.36M–
Q2 FY2025Jun 30, 2025$12.53M–

More BlossomHill Therapeutics figures

See a number that looks wrong?